Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)

Abstract

Bone metastasis and skeletal related events predict poor prognosis in men with prostate cancer.

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

“…6,9,19 Of 12 005 men diagnosed between 1990-2004 in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry, 2.4% had bone metastasis at the time of diagnosis. 6 A urology unit in Italy found bone metastasis to be present in 2.5% of 1242 newly-diagnosed prostate cancer patients from November 2002 to May 2004.…”

“…6 A urology unit in Italy found bone metastasis to be present in 2.5% of 1242 newly-diagnosed prostate cancer patients from November 2002 to May 2004. 19 Norgaard et al 9 reported that 3% of 23 087 of newly diagnosed Death from bone involvement in prostate cancer N Sathiakumar et al prostate cancer patients included in the Danish National Patient Registry in 1999-2007 presented with bone metastasis at prostate cancer diagnosis, and another 11.5% developed bone metastasis during an average follow-up period of 2.2 years. The higher proportions with bone metastases reported in these three earlier studies are difficult to interpret because the investigators did not provide data on the distribution of prostate cancer patients by stage at diagnosis.…”

“…The Danish National Patient Registrybased study reported similar results. 9 SREs are common in metastatic prostate cancer due to frequent occurrence of bone metastasis. 25,26,27 SREs have a considerable impact on patients' quality of life as they affect patients' general well-being and the ability to perform basic functions of daily living.…”

“…5 Data are limited on the occurrence and outcomes of bone metastasis among elderly men who develop prostate cancer. A few population-based observational studies have reported results pertaining to the occurrence bone metastases and SREs among prostate cancer patients, [6][7][8][9] but none has focused on older men. We therefore quantified the impact of bone metastasis and SREs on mortality among older prostate cancer patients in the US by analyzing a combined population-based cancer registry and Medicare claims database.…”

An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions

“…Bone metastases in PCa patients have mostly been characterized as osteogenic lesions. 19,20 Serum ALP, which is considered a bone formation marker and is usually present at a higher level during osteoblastic activity, including the presence of osteogenic metastases, has been used as a biomarker for bone metastasis in various types of malignant tumours. [21][22][23][24] However, because ALP is produced not only by osteoblasts but also by various other organs, including the liver, it is not a specific biomarker for bone metastasis in PCa patients.…”